nach oben

Erschienen in:

01.03.2021 | Review Article

Antiplatelet Drugs for Neurointerventions: Part 2 Clinical Applications

verfasst von: Samuel Pearce, Julian T. Maingard, Hong Kuan Kok, Christen D. Barras, Jeremy H. Russell, Joshua A. Hirsch, Ronil V. Chandra, Ash Jhamb, Vincent Thijs, Mark Brooks, Hamed Asadi

Erschienen in: Clinical Neuroradiology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Endovascular techniques have expanded to include balloon and stent-assistance, flow diversion and individualized endovascular occlusion devices, to widen the treatment spectrum for more complex aneurysm morphologies. While usually well-tolerated by patients, endovascular treatment of intracranial aneurysms carries the risk of complications, with procedure-related ischemic complications being the most common. Several antiplatelet agents have been studied in a neurointerventional setting for both prophylaxis and in the setting of intraprocedural thrombotic complications. Knowledge of these antiplatelet agents, evidence for their use and common dosages is important for the practicing neurointerventionist to ensure the proper application of these agents.

Part one of this two-part review focused on basic platelet physiology, pharmacology of common antiplatelet medications and future directions and therapies. Part two focuses on clinical applications and evidence based therapeutic regimens.

Thompson BG, Brown RD Jr, Amin-Hanjani S, Broderick JP, Cockroft KM, Connolly ES Jr, Duckwiler GR, Harris CC, Howard VJ, Johnston SC, Meyers PM, Molyneux A, Ogilvy CS, Ringer AJ, Torner J; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention; American Heart Association; American Stroke Association. Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(8):2368–400.PubMedCrossRef

Molyneux AJ, Birks J, Clarke A, Sneade M, Kerr RS. The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms: 18 year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT). Lancet. 2015;385(9969):691–7.PubMedPubMedCentralCrossRef

Maingard J, Phan K, Lamanna A, Kok HK, Barras CD, Russell J, Hirsch JA, Chandra RV, Thijs V, Brooks M, Asadi H. Rescue Intracranial Stenting After Failed Mechanical Thrombectomy for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. World Neurosurg. 2019;132:e235–45.PubMedCrossRef

Assis Z, Menon BK, Goyal M, Demchuk AM, Shankar J, Rempel JL, Roy D, Poppe AY, Yang V, Lum C, Dowlatshahi D, Thornton J, Choe H, Burns PA, Frei DF, Baxter BW, Hill MD; ESCAPE Trialists. Acute ischemic stroke with tandem lesions: technical endovascular management and clinical outcomes from the ESCAPE trial. J Neurointerv Surg. 2018;10(5):429–33.CrossRef

Algra AM, Lindgren A, Vergouwen MDI, Greving JP, van der Schaaf IC, van Doormaal TPC, Rinkel GJE. Procedural Clinical Complications, Case-Fatality Risks, and Risk Factors in Endovascular and Neurosurgical Treatment of Unruptured Intracranial Aneurysms: A Systematic Review and Meta-analysis. JAMA Neurol. 2019;76(3):282–93.PubMedCrossRef

Yamada NK, Cross DT 3rd, Pilgram TK, Moran CJ, Derdeyn CP, Dacey RG Jr. Effect of antiplatelet therapy on thromboembolic complications of elective coil embolization of cerebral aneurysms. AJNR Am J Neuroradiol. 2007;28(9):1778–82.PubMedPubMedCentralCrossRef

Tonetti DA, Jankowitz BT, Gross BA. Antiplatelet Therapy in Flow Diversion. Neurosurgery. 2020;86(Suppl 1):S47–52.PubMedCrossRef

Chandra RV, Chan NC, Leslie-Mazwi TM, Mehta BP, Hirsch JA. Platelet function testing: does a randomized controlled trial settle the debate? J Neurointerv Surg. 2016;8(8):768–9.CrossRef

Lim ST, Thijs V, Murphy SJX, Fernandez-Cadenas I, Montaner J, Offiah C, Marquardt L, Kelly PJ, Bath PM, Lim SY, Ford GA, Norrving B, Cox D, Prodan CI, Barber PA, Werring DJ, Perry R, Zgaga L, Dawson J, McCabe DJH. Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis. J Neurol. 2020. https://doi.org/10.1007/s00415-020-09932-yCrossRefPubMedPubMedCentral

10.

Pearce S, Maingard JT, Li K, Kok HK, Barras CD, Russell JH, Hirsch JA, Chandra RV, Jhamb A, Thijs V, Brooks M, Asadi H. Antiplatelet Drugs for Neurointerventions: Part 1 Clinical Pharmacology. Clin Neuroradiol. 2020. https://doi.org/10.1007/s00062-020-00910-5CrossRefPubMed

11.

Almekhlafi MA, Al Sultan AS, Kuczynski AM, Brinjikji W, Menon BK, Hill MD, Goyal M. Antiplatelet therapy for prevention of thromboembolic complications in coiling-only procedures for unruptured brain aneurysms. J Neurointerv Surg. 2020;12(3):298–302.CrossRef

12.

Skukalek SL, Winkler AM, Kang J, Dion JE, Cawley CM, Webb A, Dannenbaum MJ, Schuette AJ, Asbury B, Tong FC. Effect of antiplatelet therapy and platelet function testing on hemorrhagic and thrombotic complications in patients with cerebral aneurysms treated with the pipeline embolization device: a review and meta-analysis. J Neurointerv Surg. 2016;8(1):58–65.CrossRef

13.

Li S, Wang D, Tian Y, Wei H, Zhou Z, Liu L, Wang D, Dong JF, Jiang R, Zhang J. Aspirin Inhibits Degenerative Changes of Aneurysmal Wall in a Rat Model. Neurochem Res. 2015;40(7):1537–45.PubMedCrossRef

14.

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T. Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol. 2014;6:51.PubMedPubMedCentral

15.

Zeymer U, Hohlfeld T, Vom Dahl J, Erbel R, Münzel T, Zahn R, Roitenberg A, Breitenstein S, Pap ÁF, Trenk D. Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE). Thromb Haemost. 2017;117(03):625–35.PubMedCrossRef

16.

Büttner T, Hellwig K, Müller T, Kuhn W. Intravenously administered acetylsalicylic acid in combination with low-dose heparin in acute ischemic stroke: a safety analysis. Clin Neuropharmacol. 1998;21(1):48–51.PubMed

17.

Goertler M, Baeumer M, Kross R, Blaser T, Lutze G, Jost S, Wallesch CW. Rapid decline of cerebral microemboli of arterial origin after intravenous acetylsalicylic acid. Stroke. 1999;30(1):66–9.PubMedCrossRef

18.

Broeg-Morvay A, Mordasini P, Slezak A, Liesirova K, Meisterernst J, Schroth G, Arnold M, Jung S, Mattle HP, Gralla J, Fischer U. Does Antiplatelet Therapy during Bridging Thrombolysis Increase Rates of Intracerebral Hemorrhage in Stroke Patients? PLoS One. 2017;12(1):e0170045.PubMedPubMedCentralCrossRef

19.

Behme D, Mpotsaris A, Zeyen P, Psychogios MN, Kowoll A, Maurer CJ, Joachimski F, Liman J, Wasser K, Kabbasch C, Berlis A, Knauth M, Liebig T, Weber W. Emergency Stenting of the Extracranial Internal Carotid Artery in Combination with Anterior Circulation Thrombectomy in Acute Ischemic Stroke: A Retrospective Multicenter Study. AJNR Am J Neuroradiol. 2015;36(12):2340–5.PubMedPubMedCentralCrossRef

20.

Ogbole GI, Owolabi MO, Yusuf BP. White matter changes on magnetic resonance imaging: a risk factor for stroke in an African population? J Stroke Cerebrovasc Dis. 2013;22(7):e227–33.PubMedCrossRef

21.

Rodrigues M, Cunha A, Figueiredo S, Carvalho A, Veloso M, Barros P, Gregório T, Paredes L, Pinho J, Castro S, Ribeiro M. Emergent carotid artery stenting in atherosclerotic disease of the internal carotid artery with tandem intracranial occlusion. J Neurol Sci. 2018;387:196–8.PubMedCrossRef

22.

Díaz-Pérez J, Parrilla G, Espinosa de Rueda M, Cabrera-Maqueda JM, García-Villalba B, Alba-Isasi MT, Morales A, Zamarro J. Mechanical Thrombectomy in Acute Stroke Due to Carotid Occlusion: A Series of 153 Consecutive Patients. Cerebrovasc Dis. 2018;46(3–4):132–41.CrossRef

23.

Chalos V, A van de Graaf R, Roozenbeek B, C G M van Es A, M den Hertog H, Staals J, van Dijk L, F M Jenniskens S, J van Oostenbrugge R, H van Zwam W, B W E M Roos Y, B L M Majoie C, F Lingsma H, van der Lugt A, W J Dippel D; MR CLEAN-MED investigators. Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke. The effect of periprocedural medication: acetylsalicylic acid, unfractionated heparin, both, or neither (MR CLEAN-MED). Rationale and study design. Trials. 2020;21(1):644.CrossRef

24.

Ries T, Buhk JH, Kucinski T, Goebell E, Grzyska U, Zeumer H, Fiehler J. Intravenous administration of acetylsalicylic acid during endovascular treatment of cerebral aneurysms reduces the rate of thromboembolic events. Stroke. 2006;37(7):1816–21.PubMedCrossRef

25.

Girdhar G, Li J, Kostousov L, Wainwright J, Chandler WL. In-vitro thrombogenicity assessment of flow diversion and aneurysm bridging devices. J Thromb Thrombolysis. 2015;40(4):437–43.PubMedCrossRef

26.

Henkes H, Bhogal P, Aguilar Pérez M, Lenz-Habijan T, Bannewitz C, Peters M, Sengstock C, Ganslandt O, Lylyk P, Monstadt H. Anti-thrombogenic coatings for devices in neurointerventional surgery: Case report and review of the literature. Interv Neuroradiol. 2019;25(6):619–27.PubMedPubMedCentralCrossRef

27.

Orlov K, Kislitsin D, Strelnikov N, Berestov V, Gorbatykh A, Shayakhmetov T, Seleznev P, Tasenko A. Experience using pipeline embolization device with Shield Technology in a patient lacking a full postoperative dual antiplatelet therapy regimen. Interv Neuroradiol. 2018;24(3):270–3.PubMedPubMedCentralCrossRef

28.

Kang HS, Han MH, Kwon BJ, Jung C, Kim JE, Kwon OK, Oh CW. Is clopidogrel premedication useful to reduce thromboembolic events during coil embolization for unruptured intracranial aneurysms? Neurosurgery. 2010;67(5):1371–6; discussion 1376.PubMedCrossRef

29.

Serebruany VL, Malinin AI, Ziai W, Pokov AN, Bhatt DL, Alberts MJ, Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. Stroke. 2005;36(10):2289–92.PubMedCrossRef

30.

Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018;379(3):215–25.PubMedPubMedCentralCrossRef

31.

Schrör K. Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vasc Med. 1998;3(3):247–51.PubMedCrossRef

32.

Matsumoto Y, Kondo R, Matsumori Y, Shimizu H, Takahashi A, Tominaga T. Antiplatelet therapy for prevention of thromboembolic complications associated with coil embolization of unruptured cerebral aneurysms. Drugs R D. 2012;12(1):1–7.PubMedPubMedCentralCrossRef

33.

Sibbing D, Stegherr J, Braun S, Mehilli J, Schulz S, Seyfarth M, Kastrati A, von Beckerath N, Schömig A. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol. 2010;55(6):558–65.PubMedCrossRef

34.

Diehl P, Halscheid C, Olivier C, Helbing T, Bode C, Moser M. Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clin Res Cardiol. 2011;100(9):765–71.PubMedCrossRef

35.

Schulz S, Angiolillo DJ, Antoniucci D, Bernlochner I, Hamm C, Jaitner J, Laugwitz KL, Mayer K, von Merzljak B, Morath T, Neumann FJ, Richardt G, Ruf J, Schömig G, Schühlen H, Schunkert H, Kastrati A; Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. J Cardiovasc Transl Res. 2014;7(1):91–100.PubMedCrossRef

36.

Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(1):66.e9–16.CrossRef

37.

Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429–36.PubMedCrossRef

38.

Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite. J Thromb Haemost. 2007;5(7):1545–51. Erratum in: J Thromb Haemost. 2007;5:1995.PubMedCrossRef

39.

Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166–73.PubMedCrossRef

40.

Payne CD, Li YG, Small DS, Ernest CS 2nd, Farid NA, Jakubowski JA, Brandt JT, Salazar DE, Winters KJ. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol. 2007;50(5):555–62.PubMedCrossRef

41.

Capranzano P, Tamburino C, Capodanno D, Miccichè E, D’Urso L, Calvi V, Angiolillo DJ, Tamburino C. Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thromb Haemost. 2011;105(06):1149–57.

42.

Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF, Hahalis G, Athanassiadou A. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv. 2011;4(4):403–10.PubMedCrossRef

43.

Small DS, Farid NA, Payne CD, Konkoy CS, Jakubowski JA, Winters KJ, Salazar DE. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet. 2010;49(12):777–98.PubMedCrossRef

44.

Akbari SH, Reynolds MR, Kadkhodayan Y, Cross DT 3rd, Moran CJ. Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg. 2013;5(4):337–43.CrossRef

45.

Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723–31.PubMedCrossRef

46.

Cho WS, Lee J, Ha EJ, Kim KH, Lee J, Cho YD, Kim JE, Han MH, Kang HS. Low-Dose Prasugrel vs Clopidogrel-Based Tailored Premedication for Endovascular Treatment of Cerebral Aneurysms. Neurosurgery. 2019;85(1):E52–9.PubMedCrossRef

47.

Choi HH, Lee JJ, Cho YD, Han MH, Cho WS, Kim JE, An SJ, Mun JH, Yoo DH, Kang HS. Antiplatelet Premedication for Stent-Assisted Coil Embolization of Intracranial Aneurysms: Low-Dose Prasugrel vs Clopidogrel. Neurosurgery. 2018;83(5):981–8.PubMedCrossRef

48.

Ha EJ, Cho WS, Kim JE, Cho YD, Choi HH, Kim T, Bang JS, Hwang G, Kwon OK, Oh CW, Han MH, Kang HS. Prophylactic Antiplatelet Medication in Endovascular Treatment of Intracranial Aneurysms: Low-Dose Prasugrel versus Clopidogrel. AJNR Am J Neuroradiol. 2016;37(11):2060–5.PubMedPubMedCentralCrossRef

49.

Kim MS, Jo KI, Yeon JY, Kim JS, Kim KH, Jeon P, Hong SC. Association between Postprocedural Infarction and Antiplatelet Drug Resistance after Coiling for Unruptured Intracranial Aneurysms. AJNR Am J Neuroradiol. 2016;37(6):1099–105.PubMedPubMedCentralCrossRef

50.

Sedat J, Chau Y, Gaudart J, Sachet M, Beuil S, Lonjon M. Prasugrel versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms. Interv Neuroradiol. 2017;23(1):52–9.PubMedCrossRef

51.

Cagnazzo F, Perrini P, Lefevre PH, Gascou G, Dargazanli C, Riquelme C, Derraz I, di Carlo D, Bonafe A, Costalat V. Comparison of Prasugrel and Clopidogrel Used as Antiplatelet Medication for Endovascular Treatment of Unruptured Intracranial Aneurysms: A Meta-Analysis. AJNR Am J Neuroradiol. 2019;40(4):681–6.PubMedPubMedCentral

52.

Delgado Almandoz JE, Crandall BM, Scholz JM, Fease JL, Anderson RE, Kadkhodayan Y, Tubman DE. Last-recorded P2Y12 reaction units value is strongly associated with thromboembolic and hemorrhagic complications occurring up to 6 months after treatment in patients with cerebral aneurysms treated with the pipeline embolization device. AJNR Am J Neuroradiol. 2014;35(1):128–35.CrossRef

53.

Xia P, He C, Chen L, Zou L, Sun S, Cui P, Wang W. Efficacy and safety of prasugrel therapy for intracranial aneurysms with endovascular treatment: A meta-analysis. J Neurol Sci. 2019;397:174–8.PubMedCrossRef

54.

Hanel RA, Taussky P, Dixon T, Miller DA, Sapin M, Nordeen JD, Tawk RG, Navarro R, Johns G, Freeman WD. Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. J Neurointerv Surg. 2013. https://doi.org/10.1136/neurintsurg-2013-010699CrossRef

55.

Narata AP, Amelot A, Bibi R, Herbreteau D, Angoulvant D, Gruel Y, Janot K. Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms. Neurosurgery. 2018;84(1):77–83. https://doi.org/10.1093/neuros/nyy002CrossRef

56.

Davis K, Morrison C. Ticagrelor for Neuroendovascular Procedures: A Case Series. J Pharm Pract. 2018;31(1):115–9.PubMedCrossRef

57.

Moore JM, Adeeb N, Shallwani H, Gupta R, Patel AS, Griessenauer CJ, Youn R, Siddiqui A, Ogilvy CS, Thomas AJ. A Multicenter Cohort Comparison Study of the Safety, Efficacy, and Cost of Ticagrelor Compared to Clopidogrel in Aneurysm Flow Diverter Procedures. Neurosurgery. 2017;81(4):665–71.PubMedCrossRef

58.

Adeeb N, Griessenauer CJ, Foreman PM, Moore JM, Shallwani H, Motiei-Langroudi R, Alturki A, Siddiqui AH, Levy EI, Harrigan MR, Ogilvy CS, Thomas AJ. Use of Platelet Function Testing Before Pipeline Embolization Device Placement: A Multicenter Cohort Study. Stroke. 2017;48(5):1322–30.PubMedCrossRef

59.

Atallah E, Saad H, Bekelis K, Chalouhi N, Tjoumakaris S, Hasan D, Eller J, Stidd D, Rosenwasser RH, Jabbour P. The use of alternatives to clopidogrel in flow-diversion treatment with the Pipeline embolization device. J Neurosurg. 2018;129(5):1130–5.CrossRef

60.

Griessenauer CJ, Ogilvy CS, Foreman PM, Chua MH, Harrigan MR, He L, Fusco MR, Mocco JD, Stapleton CJ, Patel AB, Sonig A, Siddiqui AH, Thomas AJ. Pipeline Embolization Device for Small Intracranial Aneurysms: Evaluation of Safety and Efficacy in a Multicenter Cohort. Neurosurgery. 2017;80(4):579–87.PubMedCrossRef

61.

Soize S, Foussier C, Manceau PF, Litré CF, Backchine S, Gawlitza M, Pierot L. Comparison of two preventive dual antiplatelet regimens for unruptured intracranial aneurysm embolization with flow diverter/disrupter: A matched-cohort study comparing clopidogrel with ticagrelor. J Neuroradiol. 2019;46(6):378–83.PubMedCrossRef

62.

Podlasek A, Al Sultan AA, Assis Z, Kashani N, Goyal M, Almekhlafi MA. Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis. J Neurointerv Surg. 2019. https://doi.org/10.1136/neurintsurg-2019-014996CrossRef

63.

Mohammaden MH, English SW, Stapleton CJ, Khedr E, Shoyb A, Hegazy A, Elbassiouny A. Safety and efficacy of ticagrelor as single antiplatelet therapy in prevention of thromboembolic complications associated with the Pipeline Embolization Device (PED): multicenter experience. J Neurointerv Surg. 2020;12(11):1113–6.CrossRef

64.

Abdennour L, Sourour N, Drir M, Premat K, Shotar E, Taylor G, Godier A, Mathout J, Lenck S, Bernard R, Carpentier A, Degos V, Clarençon F. Preliminary Experience with Cangrelor for Endovascular Treatment of Challenging Intracranial Aneurysms. Clin Neuroradiol. 2020;30(3):453–61. https://doi.org/10.1007/s00062-019-00811-2CrossRefPubMed

65.

Linfante I, Ravipati K, Starosciak AK, Reyes D, Dabus G. Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention. J Neurointerv Surg. 2021;13(1):30–2. https://doi.org/10.1136/neurintsurg-2020-015841CrossRef

66.

Entezami P, Holden DN, Boulos AS, Paul AR, Field NC, Nourollahzadeh E, Yamamoto J, Dalfino JC. Cangrelor dose titration using platelet function testing during cerebrovascular stent placement. Interv Neuroradiol. 2020. https://doi.org/10.1177/1591019920936923CrossRefPubMedPubMedCentral

67.

Cortez GM, Monteiro A, Sourour N, Clarençon F, Elhorany M, Grigoryan M, Mirza S, Dabus G, Linfante I, Aguilar-Salinas P, Murtaza Y, Aghaebrahim A, Sauvageau E, Hanel RA. The use of cangrelor in neurovascular interventions: a multicenter experience. Neuroradiology. 2020. https://doi.org/10.1007/s00234-020-02599-2. Epub ahead of print.CrossRefPubMed

68.

Ihn YK, Shin SH, Baik SK, Choi IS. Complications of endovascular treatment for intracranial aneurysms: Management and prevention. Interv Neuroradiol. 2018;24(3):237–45.PubMedPubMedCentralCrossRef

69.

Brinjikji W, McDonald JS, Kallmes DF, Cloft HJ. Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms. Stroke. 2013;44(5):1343–7.PubMedCrossRef

70.

Sedat J, Chau Y, Mondot L, Chemla R, Lonjon M, Padovani B. Is eptifibatide a safe and effective rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization? Single-center experience in 42 cases and review of the literature. Neuroradiology. 2014;56(2):145–53.PubMedCrossRef

71.

Mounayer C, Piotin M, Baldi S, Spelle L, Moret J. Intraarterial administration of Abciximab for thromboembolic events occurring during aneurysm coil placement. AJNR Am J Neuroradiol. 2003;24(10):2039–43.PubMedPubMedCentral

72.

Adams HP Jr, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W; AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39(1):87–99.PubMedCrossRef

73.

Ries T, Siemonsen S, Grzyska U, Zeumer H, Fiehler J. Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: single center experience in 42 cases and review of the literature. Stroke. 2009;40(5):1750–7.PubMedCrossRef

74.

Gentric JC, Brisson J, Batista AL, Ghostine J, Raymond J, Roy D, Weill A. Safety of Abciximab injection during endovascular treatment of ruptured aneurysms. Interv Neuroradiol. 2015;21(3):332–6.PubMedPubMedCentralCrossRef

75.

Aggour M, Pierot L, Kadziolka K, Gomis P, Graftieaux JP. Abciximab treatment modalities for thromboembolic events related to aneurysm coiling. Neurosurgery. 2010;67(2 Suppl Operative):503–8.CrossRef

76.

Jones RG, Davagnanam I, Colley S, West RJ, Yates DA. Abciximab for treatment of thromboembolic complications during endovascular coiling of intracranial aneurysms. AJNR Am J Neuroradiol. 2008;29(10):1925–9.PubMedPubMedCentralCrossRef

77.

Linfante I, Etezadi V, Andreone V, DeLeo M, Alehashemi S, Shaw K, Wakhloo A. Intra-arterial abciximab for the treatment of thrombus formation during coil embolization of intracranial aneurysms. J Neurointerv Surg. 2010;2(2):135–8.CrossRef

78.

Song JK, Niimi Y, Fernandez PM, Brisman JL, Buciuc R, Kupersmith MJ, Berenstein A. Thrombus formation during intracranial aneurysm coil placement: treatment with intra-arterial abciximab. AJNR Am J Neuroradiol. 2004;25(7):1147–53.PubMedPubMedCentral

79.

Martínez-Pérez R, Lownie SP, Pelz D. Intra-Arterial Use of Abciximab in Thromboembolic Complications Associated with Cerebral Aneurysm Coiling: The London Ontario Experience. World Neurosurg. 2017;100:342–50.PubMedCrossRef

80.

Sedat J, Chau Y, Gaudard J, Suissa L, Lachaud S, Lonjon M. Administration of eptifibatide during endovascular treatment of ruptured cerebral aneurysms reduces the rate of thromboembolic events. Neuroradiology. 2015;57(2):197–203.PubMedCrossRef

81.

Ramakrishnan P, Yoo AJ, Rabinov JD, Ogilvy CS, Hirsch JA, Nogueira RG. Intra-Arterial Eptifibatide in the Management of Thromboembolism during Endovascular Treatment of Intracranial Aneurysms: Case Series and a Review of the Literature. Interv Neurol. 2013;2(1):19–29.PubMedPubMedCentralCrossRef

82.

Katsaridis V, Papagiannaki C, Skoulios N, Achoulias I, Peios D. Local intra-arterial eptifibatide for intraoperative vessel thrombosis during aneurysm coiling. AJNR Am J Neuroradiol. 2008;29(7):1414–7.PubMedPubMedCentralCrossRef

83.

Yi HJ, Gupta R, Jovin TG, Tayal A, Genevro J, Gologorsky Y, Horowitz M. Initial experience with the use of intravenous eptifibatide bolus during endovascular treatment of intracranial aneurysms. AJNR Am J Neuroradiol. 2006;27(9):1856–60.PubMedPubMedCentral

84.

Daniel J, Brar J, Moussavi M, Mehta S, Korya D, Chahal H, Samaan M, Song YB, Hussain M, Kirmani J. Phase I experience of safety of eptifibatide in select patients with elective cerebral aneurysm embolization (P1.250). Neurology. 2016;86(16 Supplement):P1.250

85.

Jeong HW, Jin SC. Intra-arterial infusion of a glycoprotein IIb/IIIa antagonist for the treatment of thromboembolism during coil embolization of intracranial aneurysm: a comparison of abciximab and tirofiban. AJNR Am J Neuroradiol. 2013;34(8):1621–5.PubMedPubMedCentralCrossRef

86.

Kim S, Choi JH, Kang M, Cha JK, Huh JT. Safety and Efficacy of Intravenous Tirofiban as Antiplatelet Premedication for Stent-Assisted Coiling in Acutely Ruptured Intracranial Aneurysms. AJNR Am J Neuroradiol. 2016;37(3):508–14.PubMedPubMedCentralCrossRef

87.

Yoon CH, Lee HW, Kim YS, Lee SW, Yeom JA, Roh J, Baik SK. Preliminary Study of Tirofiban Infusion in Coil Embolization of Ruptured Intracranial Aneurysms. Neurosurgery. 2017;82(1):76–84.CrossRef

88.

Bruening R, Mueller-Schunk S, Morhard D, Seelos KC, Brueckmann H, Schmid-Elsaesser R, Straube A, Mayer TE. Intraprocedural thrombus formation during coil placement in ruptured intracranial aneurysms: treatment with systemic application of the glycoprotein IIb/IIIa antagonist tirofiban. AJNR Am J Neuroradiol. 2006;27(6):1326–31.PubMedPubMedCentral

89.

Liang XD, Wang ZL, Li TX, He YK, Bai WX, Wang YY, Zhou GY. Safety and efficacy of a new prophylactic tirofiban protocol without oral intraoperative antiplatelet therapy for endovascular treatment of ruptured intracranial aneurysms. J Neurointerv Surg. 2016;8(11):1148–53.CrossRef

90.

Samaniego EA, Gibson E, Nakagawa D, Ortega-Gutierrez S, Zanaty M, Roa JA, Jabbour P, Hasan DM. Safety of tirofiban and dual antiplatelet therapy in treating intracranial aneurysms. Stroke Vasc Neurol. 2019;4(1):36–42.PubMedPubMedCentralCrossRef

91.

Siebler M, Hennerici MG, Schneider D, von Reutern GM, Seitz RJ, Röther J, Witte OW, Hamann G, Junghans U, Villringer A, Fiebach JB. Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial. Stroke. 2011;42(9):2388–92.PubMedCrossRef

Titel: Antiplatelet Drugs for Neurointerventions: Part 2 Clinical Applications
verfasst von: Samuel Pearce
Julian T. Maingard
Hong Kuan Kok
Christen D. Barras
Jeremy H. Russell
Joshua A. Hirsch
Ronil V. Chandra
Ash Jhamb
Vincent Thijs
Mark Brooks
Hamed Asadi
Publikationsdatum: 01.03.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Neuroradiology / Ausgabe 3/2021
Print ISSN: 1869-1439
Elektronische ISSN: 1869-1447
DOI: https://doi.org/10.1007/s00062-021-00997-4

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Antiplatelet Drugs for Neurointerventions: Part 2 Clinical Applications

Abstract

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Sudden Dyspnea due to Cognard V Fistula with Superior Cerebellar Artery Supply

Central Nervous System Hemophagocytic Lymphohistiocytosis (CNS-HLH) from Leptomeningeal Anaplastic Large Cell Lymphoma

Reasons for Failed Mechanical Thrombectomy in Posterior Circulation Ischemic Stroke Patients

Response to Letter to the Editor “Keeping Late Thrombectomy Imaging Protocols Simple to Avoid Analysis Paralysis”

Epilepsy Associated with Temporal Pole Encephaloceles

Management of a DAVF in a Patient with Loeys-Dietz Syndrome Type II

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie